JNJ Pharmaceuticals: Business Review (Johnson and Johnson Ltd) - May 30, 2013 - Anticipated first data from P2 (simeprevir+IDX719+TMC647055) trial for genotype 1b and genotype 4 treatment naïves hep C patients with fibrosis (stage F0-F3) in H1 2014; Anticipated first data from P2 (simeprevir+IDX719+TMC647055) trial for genotype 1 treatment naïves hep C patients with fibrosis (stage F0-F3) in H1 2014
Anticipated P2 data • Hepatitis C Virus
|